MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma.
Jain AP, Patel K, Pinto S, Radhakrishnan A, Nanjappa V, Kumar M, Raja R, Patil AH, Kumari A, Manoharan M, Karunakaran C, Murugan S, Keshava Prasad TS, Chang X, Mathur PP, Kumar P, Gupta R, Gupta R, Khanna-Gupta A, Sidransky D, Chatterjee A, Gowda H.
Jain AP, et al. Among authors: murugan s.
Sci Rep. 2019 Dec 11;9(1):18793. doi: 10.1038/s41598-019-55208-5.
Sci Rep. 2019.
PMID: 31827134
Free PMC article.